Price T Rowe Associates Inc. MD Sells 90,098 Shares of Humana Inc. (NYSE:HUM)

Price T Rowe Associates Inc. MD lowered its position in Humana Inc. (NYSE:HUM - Free Report) by 4.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,154,340 shares of the insurance provider's stock after selling 90,098 shares during the period. Price T Rowe Associates Inc. MD owned about 1.79% of Humana worth $546,578,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of HUM. SRS Investment Management LLC bought a new stake in shares of Humana during the 4th quarter valued at $31,281,000. J. Safra Sarasin Holding AG purchased a new position in Humana during the fourth quarter valued at approximately $1,514,000. State of Tennessee Department of Treasury boosted its position in shares of Humana by 32.2% in the fourth quarter. State of Tennessee Department of Treasury now owns 44,789 shares of the insurance provider's stock worth $11,363,000 after purchasing an additional 10,919 shares during the period. TD Waterhouse Canada Inc. increased its stake in shares of Humana by 5.4% in the fourth quarter. TD Waterhouse Canada Inc. now owns 9,807 shares of the insurance provider's stock worth $2,487,000 after purchasing an additional 506 shares in the last quarter. Finally, Transce3nd LLC bought a new stake in shares of Humana during the 4th quarter valued at $38,000. Hedge funds and other institutional investors own 92.38% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts have issued reports on HUM shares. StockNews.com upgraded Humana from a "hold" rating to a "buy" rating in a research note on Monday, April 7th. JPMorgan Chase & Co. decreased their target price on Humana from $257.00 to $256.00 and set a "neutral" rating on the stock in a research note on Tuesday, February 18th. Mizuho increased their price objective on shares of Humana from $305.00 to $316.00 and gave the company an "outperform" rating in a report on Wednesday, April 9th. Morgan Stanley lowered their target price on shares of Humana from $301.00 to $285.00 and set an "equal weight" rating on the stock in a report on Wednesday, February 12th. Finally, Truist Financial lifted their price target on shares of Humana from $290.00 to $325.00 and gave the company a "hold" rating in a report on Friday, April 11th. Seventeen research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, Humana currently has a consensus rating of "Hold" and an average target price of $284.90.

Humana Trading Down 1.5 %

Shares of HUM traded down $3.91 during midday trading on Friday, hitting $263.92. The stock had a trading volume of 1,097,942 shares, compared to its average volume of 1,747,221. The stock's 50 day moving average is $266.35 and its 200 day moving average is $270.81. The firm has a market cap of $31.85 billion, a PE ratio of 26.52, a price-to-earnings-growth ratio of 2.05 and a beta of 0.62. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.76 and a quick ratio of 1.76. Humana Inc. has a 1 year low of $213.31 and a 1 year high of $406.46.

Humana (NYSE:HUM - Get Free Report) last posted its quarterly earnings data on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share for the quarter, topping analysts' consensus estimates of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. As a group, analysts forecast that Humana Inc. will post 16.47 EPS for the current fiscal year.

Humana Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, July 25th. Stockholders of record on Friday, June 27th will be issued a $0.885 dividend. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.34%. The ex-dividend date of this dividend is Friday, June 27th. Humana's payout ratio is presently 35.58%.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.